Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen
- 1 July 2003
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (10) , 1580-1581
- https://doi.org/10.1097/00002030-200307040-00028
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcomaBlood, 2002
- HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcomaNature Medicine, 2002
- Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapyAIDS, 2001
- Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patientsAIDS, 2000
- Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposiʼs sarcomaAIDS, 1998